Trials / Recruiting
RecruitingNCT06917664
Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- China National Center for Cardiovascular Diseases · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sacubitril/valsartan | Sacubitril/valsartan therapy after isolated CABG |
Timeline
- Start date
- 2025-06-05
- Primary completion
- 2026-12-01
- Completion
- 2027-06-01
- First posted
- 2025-04-08
- Last updated
- 2025-08-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06917664. Inclusion in this directory is not an endorsement.